Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests that AR-V7-positive tumors may be enriched for DNA-repair defects, perhaps rendering them more sensitive to immune-checkpoint bloc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Boudadi, Karim, Suzman, Daniel L., Anagnostou, Valsamo, Fu, Wei, Luber, Brandon, Wang, Hao, Niknafs, Noushin, White, James R., Silberstein, John L., Sullivan, Rana, Dowling, Donna, Harb, Rana, Nirschl, Thomas R., Veeneman, Brendan A., Tomlins, Scott A., Wang, Yipeng, Jendrisak, Adam, Graf, Ryon P., Dittamore, Ryan, Carducci, Michael A., Eisenberger, Mario A., Haffner, Michael C., Meeker, Alan K., Eshleman, James R., Luo, Jun, Velculescu, Victor E., Drake, Charles G., Antonarakis, Emmanuel S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2018
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033362/
https://ncbi.nlm.nih.gov/pubmed/29983880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25564
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller